Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OMER KHALID

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1174565899
CMS profile
53449
Location
NORTH CHESTERFIELD, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$13,517.81

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OMER KHALID

NPI 1174565899 · CMS profile ID 53449

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

NORTH CHESTERFIELD, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174565899?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OMER KHALID, NPI 1174565899, CMS profile ID 53449. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174565899?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). OMER KHALID, NPI 1174565899, CMS profile ID 53449. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174565899?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
OMER KHALID, NPI 1174565899, CMS profile ID 53449, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174565899?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $13,517.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $16.0802/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932814085 CMS
ABBVIE INC. $25.0302/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893054107 CMS
ABBVIE INC. $14.8602/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893054105 CMS
Janssen Biotech, Inc. $28.0701/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886717391 CMS
Gilead Sciences, Inc. $2.2601/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929577049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,804.89 82
PY2020 $11,770.02 39
PY2021 $15,142.23 94
PY2022 $13,517.81 105
PY2023 $12,026.41 86
PY2024 $1,443.12 65
PY2025 $1,166.74 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $64.26 1
PY2025 Principal investigator $363,296.94 218
PY2024 Principal investigator $421,138.97 65
PY2023 Principal investigator $304,069.18 46
PY2022 Principal investigator $14,793.00 4
PY2021 Recipient $966.70 1
PY2021 Principal investigator $42,893.08 3
PY2020 Recipient $16.38 1
PY2020 Principal investigator $20,721.20 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

219 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748124
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748126
Principal investigator 1 Genentech, Inc. $37,887.00 12/29/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610987
Principal investigator 1 Madrigal Pharmaceuticals $1,748.83 12/19/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254276
Principal investigator 1 Boehringer Ingelheim International GmbH $1,985.00 12/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748110
Principal investigator 1 Boehringer Ingelheim International GmbH $3,272.00 12/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748112
Principal investigator 1 Boehringer Ingelheim International GmbH $2,891.00 12/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748114
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $12,161.00 12/17/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211610903
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211610907
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 12/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747888
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 12/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747890
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 12/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747894
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 12/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747896
Principal investigator 1 Boehringer Ingelheim International GmbH $1,200.00 12/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747886
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 12/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747892
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748106
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748108
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747944
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747850
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747860
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747862
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747874
Principal investigator 1 Boehringer Ingelheim International GmbH $533.28 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747876
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 11/06/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747882
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747848
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747852
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747854
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747856
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747858
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747864
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747866
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747868
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747870
Principal investigator 1 Boehringer Ingelheim International GmbH $4,898.52 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747872
Principal investigator 1 Boehringer Ingelheim International GmbH $3,839.88 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747878
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747880
Principal investigator 1 Boehringer Ingelheim International GmbH $178.20 11/05/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747884
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748102
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748104
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748116
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748118
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748120
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748122
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 10/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747898
Principal investigator 1 Madrigal Pharmaceuticals $750.00 10/23/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251787
Recipient Eli Lilly and Company $64.26 10/20/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187871597
Principal investigator 1 Boehringer Ingelheim International GmbH $1,030.00 10/02/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748094
Principal investigator 1 Boehringer Ingelheim International GmbH $1,030.00 10/02/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748096
Principal investigator 1 Boehringer Ingelheim International GmbH $2,105.00 10/02/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748098
Principal investigator 1 Boehringer Ingelheim International GmbH $1,257.00 10/02/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748100
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748090
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748092
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748076
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748080
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747830
Principal investigator 1 Boehringer Ingelheim International GmbH $1,460.00 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747832
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747834
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747932
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747934
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747936
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747938
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748082
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748084
Principal investigator 1 Boehringer Ingelheim International GmbH $1.62 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748086
Principal investigator 1 Boehringer Ingelheim International GmbH $11.68 09/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748088
Principal investigator 1 Boehringer Ingelheim International GmbH $624.36 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747836
Principal investigator 1 Boehringer Ingelheim International GmbH $266.64 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747838
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747840
Principal investigator 1 Boehringer Ingelheim International GmbH $7,260.00 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747842
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747844
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747846
Principal investigator 1 Boehringer Ingelheim International GmbH $389.40 09/11/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747940
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 09/11/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747942
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748054
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748056
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/29/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748074
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/29/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748078
Principal investigator 1 Genentech, Inc. $1,039.00 08/27/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610982
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747826
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 08/26/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747828
Principal investigator 1 Boehringer Ingelheim International GmbH $1,389.00 08/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748068
Principal investigator 1 Boehringer Ingelheim International GmbH $211.00 08/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748062
Principal investigator 1 Boehringer Ingelheim International GmbH $211.00 08/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748064
Principal investigator 1 Boehringer Ingelheim International GmbH $422.00 08/18/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748066
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 08/13/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747926
Principal investigator 1 Boehringer Ingelheim International GmbH $1,395.00 08/13/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747928
Principal investigator 1 Boehringer Ingelheim International GmbH $3,905.88 08/13/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747930
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748050
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748052
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748070
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748072
Principal investigator 1 Madrigal Pharmaceuticals $75.00 07/31/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247711
Principal investigator 1 Madrigal Pharmaceuticals $1,452.00 07/31/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247713
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747816
Principal investigator 1 Boehringer Ingelheim International GmbH $735.00 07/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747818
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 07/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748048
Principal investigator 1 Genentech, Inc. $5,195.00 07/23/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610971
Principal investigator 1 Boehringer Ingelheim International GmbH $5,940.00 07/21/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748044
Principal investigator 1 Boehringer Ingelheim International GmbH $5,940.00 07/21/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748046
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/16/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747916
Principal investigator 1 Boehringer Ingelheim International GmbH $464.40 07/16/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747918
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/16/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747920
Principal investigator 1 Genentech, Inc. $4,156.00 07/16/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610974
Principal investigator 1 Boehringer Ingelheim International GmbH $307.56 07/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747922
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 07/10/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747924
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747820
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748058
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748060
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748030
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748032
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 06/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747790
Principal investigator 1 Boehringer Ingelheim International GmbH $5,084.00 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747788
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747810
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747812
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747814
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747908
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747910
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747912
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 06/24/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747914
Principal investigator 1 Madrigal Pharmaceuticals $2,005.90 06/24/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246216
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747824
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748018
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748020
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748026
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 05/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748028
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/27/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161009
Principal investigator 1 Bausch Health US, LLC $1,500.00 05/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224841526
Principal investigator 1 Bausch Health US, LLC $1,895.00 05/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224841529
Principal investigator 1 Genentech, Inc. $750.00 05/21/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610963
Principal investigator 1 GlaxoSmithKline, LLC. $2,174.34 05/15/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161029
Principal investigator 1 GlaxoSmithKline, LLC. $1,489.75 05/15/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192162226
Principal investigator 1 Boehringer Ingelheim International GmbH $220.20 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747792
Principal investigator 1 Boehringer Ingelheim International GmbH $307.56 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747794
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747796
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747798
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747800
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 05/12/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747802
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/12/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161037
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/12/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192162239
Principal investigator 1 Caris MPI, Inc. $7,600.00 05/09/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
THE CARIS BIOREPOSITORY RESEARCH PROTOCOL No dispute reported 06/30/2026 1234284684
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 05/08/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161021
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748014
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748016
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748022
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/30/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748024
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 04/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747786
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 04/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748012
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747806
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747808
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747904
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747906
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748034
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748036
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748038
Principal investigator 1 Boehringer Ingelheim International GmbH $2.16 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748040
Principal investigator 1 Boehringer Ingelheim International GmbH $11.68 04/23/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748042
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 04/17/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747782
Principal investigator 1 Boehringer Ingelheim International GmbH $1,874.00 04/11/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748010
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 04/11/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159635
Principal investigator 1 Madrigal Pharmaceuticals $1,748.83 04/08/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241910
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747780
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748006
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748008
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 03/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747978
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747980
Principal investigator 1 Genentech, Inc. $26,638.00 03/26/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610915
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 03/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747776
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747778
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 03/25/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748004
Principal investigator 1 GlaxoSmithKline, LLC. $4,803.08 03/21/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192162245
Principal investigator 1 Madrigal Pharmaceuticals $3,500.00 03/06/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240373
Principal investigator 1 Boehringer Ingelheim International GmbH $57.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747982
Principal investigator 1 Boehringer Ingelheim International GmbH $1,979.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747984
Principal investigator 1 Boehringer Ingelheim International GmbH $2,237.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747986
Principal investigator 1 Boehringer Ingelheim International GmbH $1,874.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747988
Principal investigator 1 Boehringer Ingelheim International GmbH $2,237.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747990
Principal investigator 1 Boehringer Ingelheim International GmbH $1,874.00 03/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747992
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747784
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747966
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747968
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 02/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747766
Principal investigator 1 Boehringer Ingelheim International GmbH $660.00 02/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747768
Principal investigator 1 Boehringer Ingelheim International GmbH $4,884.00 02/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747770
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747974
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/28/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747976
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 02/27/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161017
Principal investigator 1 Genentech, Inc. $21,819.00 02/26/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211610936
Principal investigator 1 GlaxoSmithKline, LLC. $1,531.33 02/24/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161025
Principal investigator 1 Madrigal Pharmaceuticals $2,152.61 02/06/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239180
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747962
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747964
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747970
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 01/31/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747972
Principal investigator 1 Madrigal Pharmaceuticals $16,796.80 01/30/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238843
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 01/28/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161013
Principal investigator 1 GlaxoSmithKline, LLC. $132.00 01/28/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192162230
Principal investigator 1 GlaxoSmithKline, LLC. $4,620.00 01/28/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192162242
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747772
Principal investigator 1 Boehringer Ingelheim International GmbH $1,131.50 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747774
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747900
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220747902
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747994
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747996
Principal investigator 1 Boehringer Ingelheim International GmbH $122.14 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747998
Principal investigator 1 Boehringer Ingelheim International GmbH $5.40 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748000
Principal investigator 1 Boehringer Ingelheim International GmbH $29.20 01/27/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220748002
Principal investigator 1 Boehringer Ingelheim International GmbH $3,255.00 01/15/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747946
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 01/15/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747948
Principal investigator 1 Boehringer Ingelheim International GmbH $3,255.00 01/15/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747950
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 01/15/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747952
Principal investigator 1 Boehringer Ingelheim International GmbH $1,979.00 01/15/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747954
Principal investigator 1 GlaxoSmithKline, LLC. $1,531.33 01/10/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192161033
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 01/03/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747956
Principal investigator 1 Madrigal Pharmaceuticals $2,844.60 01/03/2025 Non-covered Recipient Entity
GI SELECT HEALTH RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237947
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220747764
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747958
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
GI Select Health Research LLC
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220747960